Genocea Biosciences (GNCA) Tops Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. UNH
7. CVS
8. SBUX
9. AXP
10. ZETA

Go back to Genocea Biosciences (GNCA) Tops Q2 EPS by 8c

Genocea Reports Second Quarter 2015 Financial Results

August 6, 2015 8:00 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the second quarter ended June 30, 2015.

"We were extremely pleased to report positive top-line results in May from our Phase 2 dose optimization trial of GEN-003, our immunotherapy against genital herpes, which improved upon the already attractive efficacy profile from our prior Phase 1/2a trial, said Chip Clark, president and chief executive officer of Genocea. In the fourth quarter of this year, we look forward to reporting... More